ClinicalTrials.gg
RecruitingNCT06014424CALM-ITUpdated Nov 17, 2026

Cannabidiol Medication Intervention Trial

A Phase 2 interventional study of CBD and Placebo in Alzheimer Disease, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 5 sites in Canada. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sunnybrook Health Sciences Centre · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.
Updated Nov 17, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre — 8 open to participants now, 8 under way, 1 of them phase 3. Alzheimer Disease · Sunnybrook Health Sciences Centre.

Planned enrollment
4th of 13
40 · median 40
Started
2023
with 1 other
Phase 2
5 of 16
3 open now
Registered
13th of 16
by date

Among the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 13th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, or all of them as a file.
02

Study summary

CALM-IT is a Randomized, double-blind, placebo-controlled cross-over clinical trial. Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD and to identify novel biomarkers of agitation severity and treatment response.

Read the detailed description

This study will look at whether CBD is an effective treatment for agitation in Alzheimer's disease (AD). This naturally derived CBD is highly pure (99%) and made by a manufacturer who meets Health Canada guidelines Cannabis products are legal for purchase in Canada.

Agitation is common in AD and is known to correlate with physical health problems such as falls and weight loss, AD progression, and caregiver burden. Current treatments for agitation in AD are not beneficial for everyone and there are concerns regarding their safety. Treating agitation is important in improving the quality of life of AD patients and their families and there is a need to identify safer and more effective treatments for agitation in AD.

The structure of this trial is called a "cross-over study". Participants will be randomized to receive either CBD or placebo during the first of two treatment phases. They will then cross-over to the opposite treatment during the second treatment phase. Participants will be on the study treatment for a total of 19 weeks and then will be followed for 4 more weeks after finishing the study treatment. There will be 12 study visits approximately every 2 weeks.

In addition to looking at the effectiveness of CBD in treating agitation, the researchers will also look at whether it is beneficial for other relevant outcomes for patients with AD including overall neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, and pain.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • Agitation
  • Cannabinoids
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥55 years of age; female must be or must agree to comply with requirements. Males should also abide by contraceptive requirements when the partner is a woman of . Acceptable methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal; progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable; intrauterine device or intrauterine hormone-releasing system; vasectomy of a female participant's male partner (with medical assessment and confirmation of vasectomy surgical success); bilateral tubal occlusion
  2. -5 (DSM 5) criteria for Major Neurocognitive Disorder due to possible AD. Patients with Major Neurocognitive Disorder due to multiple etiologies (AD and vascular) will be included
  3. Presence of agitation based on the IPA definition at both screening and baseline
  4. If treated with cognitive-enhancing medications (cholinesterase inhibitors and/or memantine), dosage must be stable for at least 3 months prior to study randomization
  5. Availability of a primary caregiver to accompany the participant to study visits and to participate in the study. The primary caregiver must be sufficiently proficient in English to complete the required study assessments, as per investigator judgement and should spend at least 10 hours a week with the participant
  6. Willing and able to provide and/or have a Substitute Decision Maker (SDM) provide informed consent on behalf of the participant

Exclusion criteria

Exclusion Criteria:

  1. Change in psychotropic medications less than the duration of 5 half-lives of the medication in question prior to screening (e.g., concomitant antidepressants or atypical antipsychotics) and any changes during study participation
  2. to CBs, e.g. allergies to cannabis and cannabis products, potential drug-drug interactions (e.g. strong inducers/inhibitors, anticonvulsants)
  3. Uncontrolled vascular disease, clinically important cerebrovascular disease or current uncontrolled cardiovascular disease (e.g. uncontrolled hypertension, ischemic heart disease, arrhythmia and severe heart failure, cardiovascular accident in the 3 months prior to Screening (V1)), as per investigator assessment
  4. Clinically significant liver disease, (e.g., serum or aspartate aminotransferase > 2 x (ULN), or total > 1.5 x ULN) collected within one more of or at screening. The Investigator may decide to repeat the assessment to confirm clinical significance prior to screen failing the participant
  5. Clinically significant impaired renal function at screening, as per investigator assessment
  6. Currently meeting DSM 5 criteria for Major Depressive Episode Presence, or current substance dependence (excluding caffeine and nicotine) or history of other major psychiatric disorders or neurological conditions (e.g. psychotic disorders, schizophrenia, stroke, epilepsy)
  7. Clinically significant delusions and/or hallucinations (e.g. NPI-NH delusion/hallucinations subscore ≥4 or judgement of QI)
  8. Reported use of marijuana or cannabinoid-based medications, products or supplements (botanical or synthetic) within 1 week prior to randomization
  9. Systolic blood pressure (SBP) \< 90 mmHg or > 150 mmHg or diastolic blood pressure (DBP) \< 50mmHg or > 105 mmHg at screening or baseline (prior to randomization)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    CBD First

    This is a cross-over study. Both groups will receive CBD and placebo at some point during the study. Participants randomized to receive CBD first will be titrated up to a maximum dose of 800 mg/day during treatment period 1. They will then receive placebo for the second treatment period and take the same number of capsules as the CBD group.

    Drug: CBD · Drug: Placebo

  • Experimental
    Placebo First

    This is a cross-over study. Both groups will receive CBD and placebo at some point during the study. Participants randomized to receive placebo first will take the same number of capsules as the CBD group during treatment period 1. They will then receive CBD for treatment period 2 and be titrated up to a maximum dose of 800 mg/day.

    Drug: CBD · Drug: Placebo

Interventions

  • DrugCannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cannabidiol will be titrated to a maximum dose of 800mg per day.

  • DrugPlacebo

    Placebo capsules will be increased to match the CBD titration schedule.

06

What researchers measure

Primary outcomes

  1. Change in Agitation as measured by the Cohen-Mansfield Agitation Inventory (CMAI)

    A 29-point scale that measures agitation in two dimensions, verbal and physical, each of which having two poles, aggressive and on-aggressive. Scores range from 29-203 points, with a higher score indicating a worse outcome.

    Time frame: Up to 21 weeks

Secondary outcomes

  1. Change in overall Neuropsychiatric symptoms (behavior) as measured by the Neuropsychiatric Inventory - Nursing Home Scale

    NPI-NH is a caregiver-rated scale that is widely used to assess behavioral disturbances in dementia as well as caregiver distress. These behaviours include: delusions, hallucinations, agitation, aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep, appetite and eating disorders, and aberrant vocalizations. The frequency and severity of these symptoms are judged on a 4-point and 3-point scale, respectively. Scores range from 0-144 points, with a higher score indicating a worse outcome.

    Time frame: Up to 21 weeks

  2. Change in caregiver distress as measured by the Neuropsychiatric Inventory - Nursing Home Scale

    NPI-NH is a caregiver-rated scale that is widely used to assess behavioral disturbances in dementia as well as caregiver distress. These behaviours include: delusions, hallucinations, agitation, aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep, appetite and eating disorders, and aberrant vocalizations. The frequency and severity of these symptoms are judged on a 4-point and 3-point scale, respectively. Scores range from 0-144 points, with a higher score indicating a worse outcome.

    Time frame: Up to 21 weeks

  3. Change agitation symptoms as measured by the Neuropsychiatric Inventory - Clinician Scale

    NPI-C is a widely used assessment of behaviour disturbances in dementia, including: apathy agitation, delusions, hallucinations, depression, euphoria, aberrant motor behaviour, irritability, disinhibition, anxiety, sleeping, and eating.

    Time frame: Up to 21 weeks

  4. Change aggression symptoms as measured by the Neuropsychiatric Inventory - Clinician Scale

    NPI-C is a widely used assessment of behaviour disturbances in dementia, including: apathy agitation, delusions, hallucinations, depression, euphoria, aberrant motor behaviour, irritability, disinhibition, anxiety, sleeping, and eating.

    Time frame: Up to 21 weeks

  5. Change in Cognition as measured by the Standardized Mini-Mental State Examination (sMMSE) or telephone Mini-Mental State Examination (tMMSE)

    Measures global cognition, and assesses orientation to time and place, immediate recall, short-term verbal memory, calculation, language, and construct ability. Scores range from 0-30 points, with a lower score indicating a worse outcome.

    Time frame: Up to 21 weeks

  6. Change in weight

    Weight will be collected in kilograms. A change of 7% in weight will be considered clinically significant change.

    Time frame: Up to 21 weeks

  7. Change in nutritional status as measured by the Mini Nutritional Assessment - Short Form (MNA-SF)

    A structured interview consisting of 6 items that categorizes patients as malnourished, at risk of malnutrition, or of normal nutritional status. Scores range from 0-14 points, with a lower score indicating a worse outcome.

    Time frame: Up to 19 weeks

  8. Change in pain as measured using the Pain Assessment Checklist for Seniors with Limited Ability to Communicate - II (PACSLAC-II)

    A 31-item observer-rated scale assessing facial expressions, activity/body movements, social/personality/mood indicators and mental status changes. Scores range form 0-31 points, with a higher score indicating a worse outcome.

    Time frame: Up to 19 weeks

  9. Global Change assessed using the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)

    A commonly-used clinician-rated scale that quantifies clinical change (worsening, no change, or improvement), based on information regarding the patient's medical history, cognition, behaviour, and function. Scores range from 1-7, with a lower score indicating a worse outcome.

    Time frame: Up to 19 weeks

Other outcomes

  1. Number of participants experiencing Sedation measured using the Udvalg for Kliniske Undersøgelser (UKU) Side-Effect Rating Scale

    Sedation will be measured using the Sleepiness/Sedation subscale of the UKU-Side Effect Rating Scale. The UKU is a clinician-rated scale that assesses the side effects psychopharmacological medications. Scores range from 0-3, with a higher score indicating more sleepiness/sedation.

    Time frame: Up to 19 weeks

  2. Number of participants experiencing treatment-related adverse events.

    Safety will be measured using vitals (heart rate and blood pressure), physical examinations, and AE reports of dizziness, especially postural dizziness. Special attention will be paid to any falls. Clinically significant changes to vital signs and physical status will be reported. Falls will be reported as AEs.

    Time frame: Up to 25 weeks

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in the publication, after deidentification (text, tables, figures and appendices)

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication

Access criteria: Investigators whose proposed use of the data has been approved by the Principal Investigator and/or Committee as indicated in the trial authorship policy. They will be able to access individual participant data that underlie the results reported in the publication. Proposals may be submitted up to 36 months following article publication to the central contact person.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2027, 51 months after the start.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 51 months is close to that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 28, 2023
StartActual
Sep 27, 2023
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 29, 2026→Dec 2027
Nov 17, 2026
Study completion
Dec 29, 2026→Dec 2027
Nov 17, 2026
Eligibility
1 inclusion criterion edited, 1 removed; 3 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedMales or females ≥55 years of age; female must be post-menopausal or must agree to comply with contraception requirements. Males should also abide by contraceptive requirements when the partner is a woman of childbearing potential. Acceptable methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal; progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable; intrauterine device or intrauterine hormone-releasing system; vasectomy of a female subjectparticipant's male partner (with medical assessment and confirmation of vasectomy surgical success); bilateral tubal occlusion
  • RemovedsMMSE ≤24
Exclusion criteria
  • EditedVascularUncontrolled vascular disease, clinically important cerebrovascular disease or current uncontrolled cardiovascular disease (e.g. uncontrolled hypertension, ischemic heart disease, arrhythmia and severe heart failure, cardiovascular accident in the 3 months prior to Screening (V1)), as per investigator assessment
  • EditedClinically significant liver disease, as reflected by(e.g., serum alanine aminotransferase or aspartate aminotransferase > 2 x upper limit of normal (ULN), or total bilirubin > 1.5 x ULN;) collected within one more of or at screening. The Investigator may decide to repeat the assessment to confirm criterionclinical significance prior to screen failing the participant
  • RemovedSubstance-Related Disorders (excluding caffeine and nicotine)
  • EditedSystolic blood pressure (SBP) < 90 mmHg or > 150 mmHg or diastolic blood pressure (DBP) < 50mmHg or > 105 mmHg at screening or baseline (prior to randomization) or a postural drop in SBP ≥ 20 mmHg or DBP ≥ 10 mmHg at screening
Nov 17, 2026
Interventions
Added Drug: Placebo; removed Placebo. Arm changed CBD→CBD First; Placebo→Placebo First
Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Agitation -as measured by the Cohen-Mansfield Agitation Inventory (CMAI)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 21 weeks
Nov 17, 2026
Secondary outcomes
6 edited, 5 added, 1 removed
What changed in the outcomes
  • EditedChange in Cognition -as measured by the Standardized Mini-Mental State Examination (sMMSE) or telephone Mini-Mental State Examination (tMMSE)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 21 weeks
  • EditedWeightChange in weightTime frame: Baseline (0 Weeks) to 22 Weeks → Up to 21 weeks
  • EditedNutritional Status -Change in nutritional status as measured by the Mini Nutritional Assessment - Short Form (MNA-SF)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
  • EditedPain -Change in pain as measured using the Pain Assessment Checklist for Seniors with Limited Ability to Communicate - II (PACSLAC-II)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
  • EditedGlobal Change -assessed using the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Severity/Change (ADCS-CGIS/CCGIC)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
  • AddedChange in overall Neuropsychiatric symptoms (behavior) as measured by the Neuropsychiatric Inventory - Nursing Home ScaleTime frame: Up to 21 weeks
  • AddedChange in caregiver distress as measured by the Neuropsychiatric Inventory - Nursing Home ScaleTime frame: Up to 21 weeks
  • AddedChange agitation symptoms as measured by the Neuropsychiatric Inventory - Clinician ScaleTime frame: Up to 21 weeks
  • AddedChange aggression symptoms as measured by the Neuropsychiatric Inventory - Clinician ScaleTime frame: Up to 21 weeks
  • RemovedBehavior - Neuropsychiatric Inventory - Clinician Scale (NPI-C Agitation/NPI-NH)Time frame: Baseline (0 Weeks) to 22 Weeks
  • Editedother outcomeNumber of participants experiencing Sedation -measured using the Udvalg for Kliniske Undersøgelser (UKU) Side-Effect Rating ScaleTime frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
  • Addedother outcomeNumber of participants experiencing treatment-related adverse events.Time frame: Up to 25 weeks
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Centre for Addiction and Mental Health · Toronto, CanadaContact B•••@camh.ca→C•••@camh.ca
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Dec 29, 2026→Dec 2027
    Study completion Dec 29, 2026→Dec 2027
    Eligibility 1 inclusion criterion edited, 1 removed; 3 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMales or females ≥55 years of age; female must be post-menopausal or must agree to comply with contraception requirements. Males should also abide by contraceptive requirements when the partner is a woman of childbearing potential. Acceptable methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal; progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable; intrauterine device or intrauterine hormone-releasing system; vasectomy of a female subjectparticipant's male partner (with medical assessment and confirmation of vasectomy surgical success); bilateral tubal occlusion
    • RemovedsMMSE ≤24
    Exclusion criteria
    • EditedVascularUncontrolled vascular disease, clinically important cerebrovascular disease or current uncontrolled cardiovascular disease (e.g. uncontrolled hypertension, ischemic heart disease, arrhythmia and severe heart failure, cardiovascular accident in the 3 months prior to Screening (V1)), as per investigator assessment
    • EditedClinically significant liver disease, as reflected by(e.g., serum alanine aminotransferase or aspartate aminotransferase > 2 x upper limit of normal (ULN), or total bilirubin > 1.5 x ULN;) collected within one more of or at screening. The Investigator may decide to repeat the assessment to confirm criterionclinical significance prior to screen failing the participant
    • RemovedSubstance-Related Disorders (excluding caffeine and nicotine)
    • EditedSystolic blood pressure (SBP) < 90 mmHg or > 150 mmHg or diastolic blood pressure (DBP) < 50mmHg or > 105 mmHg at screening or baseline (prior to randomization) or a postural drop in SBP ≥ 20 mmHg or DBP ≥ 10 mmHg at screening
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Agitation -as measured by the Cohen-Mansfield Agitation Inventory (CMAI)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 21 weeks
    Secondary outcomes 6 edited, 5 added, 1 removed
    What changed in the outcomes
    • EditedChange in Cognition -as measured by the Standardized Mini-Mental State Examination (sMMSE) or telephone Mini-Mental State Examination (tMMSE)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 21 weeks
    • EditedWeightChange in weightTime frame: Baseline (0 Weeks) to 22 Weeks → Up to 21 weeks
    • EditedNutritional Status -Change in nutritional status as measured by the Mini Nutritional Assessment - Short Form (MNA-SF)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
    • EditedPain -Change in pain as measured using the Pain Assessment Checklist for Seniors with Limited Ability to Communicate - II (PACSLAC-II)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
    • EditedGlobal Change -assessed using the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Severity/Change (ADCS-CGIS/CCGIC)Time frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
    • AddedChange in overall Neuropsychiatric symptoms (behavior) as measured by the Neuropsychiatric Inventory - Nursing Home ScaleTime frame: Up to 21 weeks
    • AddedChange in caregiver distress as measured by the Neuropsychiatric Inventory - Nursing Home ScaleTime frame: Up to 21 weeks
    • AddedChange agitation symptoms as measured by the Neuropsychiatric Inventory - Clinician ScaleTime frame: Up to 21 weeks
    • AddedChange aggression symptoms as measured by the Neuropsychiatric Inventory - Clinician ScaleTime frame: Up to 21 weeks
    • RemovedBehavior - Neuropsychiatric Inventory - Clinician Scale (NPI-C Agitation/NPI-NH)Time frame: Baseline (0 Weeks) to 22 Weeks
    • Editedother outcomeNumber of participants experiencing Sedation -measured using the Udvalg for Kliniske Undersøgelser (UKU) Side-Effect Rating ScaleTime frame: Baseline (0 Weeks) to 22 Weeks → Up to 19 weeks
    • Addedother outcomeNumber of participants experiencing treatment-related adverse events.Time frame: Up to 25 weeks
    Interventions Added Drug: Placebo; removed Placebo. Arm changed CBD→CBD First; Placebo→Placebo First
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Centre for Addiction and Mental Health · Toronto, CanadaContact B•••@camh.ca→C•••@camh.ca
    + 8 other changes: verification date, oversight details, description, conditions, design details, site details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06014424
Collaborators
Weston Brain Institute
Responsible party
Sponsor
First posted
Aug 28, 2023
Start date
Sep 27, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

CALM-IT Coordinating Centre
Contact
CALM-IT@sunnybrook.ca
416-480-6100 ext. 5630
Krista L. Lanctot, PhD
principal investigator · Sunnybrook Research Institute
Giovanni Marotta
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion